Please login to the form below

Not currently logged in
Email:
Password:

NICE issues final guidance on liraglutide

NICE publishes final guidance on the use of liraglutide (brand name Victoza) for people with type 2 diabetes in England, Wales and Northern Ireland

As part of its Single Technology Appraisal (STA) process to "fast track" appraisals of single technologies for single indications, the National Institute for Health and Clinical Excellence (NICE) has published final guidance on the use of liraglutide (brand name Victoza), a long-acting glucagon-like peptide-1 (GLP-1) analog, developed by Novo Nordisk, for patients with type 2 diabetes in England, Wales and Northern Ireland. 

NICE recommends once-daily liraglutide 1.2mg as a clinically- and cost-effective therapy in combination with two oral anti-diabetic tablets for the control of specific subgroups of people with type 2 diabetes detailed in the guidance.

It also recommends, irrespective of BMI, that liraglutide 1.2mg be used in combination with just one oral anti-diabetic tablet if other tablets are unsuitable in combination with current treatments or cannot be taken due to intolerances.

The new guidance instructs the National Health Service (NHS) to provide mandatory funding for liraglutide. Primary Care Trusts (PCTs) must find funding for the drug within three months for the appropriate patients as indicated by the guidance.

Commenting on the decision, Dr Marc Evans, consultant diabetologist at the Llandough Hospital in Cardiff, said: "Liraglutide represents a valuable option for patients with type 2 diabetes and their healthcare professionals. This is a significant step towards achieving health equality for people in England, Wales and Northern Ireland who qualify for treatment with liraglutide, which now requires mandatory funding from each PCT (Primary Care Trust)."

Liraglutide was approved by the European Medicines Agency (EMA) on July 3, 2009 and by the US Food and Drug Administration (FDA) for the treatment of type 2 diabetes in some adults on January 25, 2010.

27th October 2010

From: Healthcare

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

4 ways to recruit Alzheimer’s disease patients for your clinical trial
What key things do you need to remember to reach patients living with Alzheimer’s disease?...
competitive intelligence
Integrating competitive intelligence into business development, licensing and M&A strategy
The advantages of partnering with a competitive intelligence or knowledge management team...
reaching HCPs during pandemic
Reaching patients and HCPs during the pandemic
COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...

Infographics